Morphic price target raised to $56 from $45 at SVB Securities

SVB Securities analyst Thomas Smith raised the firm’s price target on Morphic to $56 from $45 driven by incrementally higher probability-of-success assumptions for lead product candidate MORF-057 in both ulcerative colitis and Crohn’s disease. The firm keeps an Outperform rating on the shares.